WallStSmart

Agenus Inc (AGEN)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 431% more annual revenue ($606.42M vs $114.20M). AGEN leads profitability with a 0.1% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. AGEN earns a higher WallStSmart Score of 48/100 (D+).

AGEN

Hold

48

out of 100

Grade: D+

Growth: 6.0Profit: 4.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: -14.23

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AGEN3 strengths · Avg: 9.3/10
Operating MarginProfitability
42.1%10/10

Strong operational efficiency at 42.1%

Debt/EquityHealth
-0.1710/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
27.5%8/10

Revenue surging 27.5% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AGEN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$142.46M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.1%3/10

0.1% margin — thin

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AGEN

The strongest argument for AGEN centers on Operating Margin, Debt/Equity, Revenue Growth. Revenue growth of 27.5% demonstrates continued momentum. PEG of 1.44 suggests the stock is reasonably priced for its growth.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : AGEN

The primary concerns for AGEN are EPS Growth, Market Cap, Profit Margin. Thin 0.1% margins leave little buffer for downturns.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

AGEN profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.

AGEN carries more volatility with a beta of 1.67 — expect wider price swings.

AGEN is growing revenue faster at 27.5% — sustainability is the question.

AGEN generates stronger free cash flow (-17M), providing more financial flexibility.

Bottom Line

AGEN scores higher overall (48/100 vs 39/100) and 27.5% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agenus Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?